Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in Its Artistry-1 Clinical Trial of Nemvaleukin, Its Lead Engineered Fusion Protein, in the Journal for Immunotherapy of Cancer
Mural Oncology宣佈發表文章，強調其領先的重組融合蛋白Nemvaleukin在Artistry-1臨床試驗中顯示出良好的抗腫瘤臨床活性，刊登於《癌症免疫治療雜誌》
